The PCAge clinical ageing clock identifies healthy and unhealthy ageing patterns. Using ACE-Is or ARBs reduces mortality risk and slows biological age acceleration, offering a proactive approach to ageing and age-related diseases.
- Identification of ageing trajectories with PCAge: The PCAge, a principal component-based clinical ageing clock, offers a nuanced understanding of the ageing process. It differentiates between healthy and unhealthy ageing trajectories, providing personalised insights into an individual’s ageing journey
- Role of ACE-Is and ARBs in clinical parameters: Angiotensin-converting-enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) have been found to normalise several clinical parameters. These medications positively impact renal and cardiac function, both crucial systems that can be affected by ageing. Additionally, they help mitigate inflammation, a factor associated with many age-related diseases
- Proactive treatment reduces mortality risk: Using ACE-I/ARBs proactively can lead to a decreased risk of future mortality. This suggests that these drugs can potentially extend life by addressing underlying ageing mechanisms
Reference: Fong, Sheng. “The principal component-based clinical aging clock (PCAge) identifies signatures of healthy aging and provides normative targets for clinical intervention.” medRxiv, 16 July 2023, https://www.medrxiv.org/content/10.1101/2023.07.14.23292604v1. Note: at the time of publishing, the article above is a preprint.